Publications from our Team
Dr. David Hanley Osteoporosis Centre
1.
Billington EO, Hasselaar C, Kembel L, Miyagishima RC, Arain MA. Effectiveness and Cost of Using Facebook Recruitment to Elicit Canadian Women’s Perspectives on Bone Health and Osteoporosis: A Cross-sectional Survey Study. Submitted to J Med Internet Res (Apr 2023).
2.
Billington EO, Miyagishima RC, Hasselaar C, Arain M. Women’s Perspectives Regarding Osteoporosis, Fracture Risk, and Pharmacologic Treatment: A cross-sectional study. In press at Osteoporosis International.
3.
Kline GA, Holmes DT. Bone turnover markers for assessment of anti-resorptive effect in clinical practice: a good idea meets the problem of measurement uncertainty. Clin Biochem 2023 (in press).
4.
Kline GA, Morin SM, Lix, LM, Leslie WL. A population-based registry study of extended bisphosphonate use: minimal shift after landmark publications about shorter treatments. JBMR 2023 *selected as highlight article for July 2023 ASBMR newsletter.
5.
Xu L, Leslie WD, Kline GA. Multiple spontaneous vertebral fractures in a younger post menopausal woman upon stopping denosumab therapy. J Endo Soc Case Reports 2023 (in press) ** selected as the case of the month, July 2023.
6.
Ardebili AA, Aghajafari F, Fu T, Dunnewold N, Billington EO. Bisphosphonates preserve bone mineral density and suppress bone turnover markers in early menopausal women: A systematic review and meta-analysis of randomized trials. In press at JBMR Plus.
2022
1.
Billington EO, Binkley N, Krueger D, Kline GA, Leslie BL. Automatic Soft Tissue Detection Failure in DXA: The 4% Fat Error. J Clin Densitom 2022; 10.1016/j.jocd.2022.11.001.
2.
Kline GA, Morin SM, Lix L, Leslie WD. Apparent “Rapid Loss” After Short-interval Post-menopausal BMD Testing Among Healthy Women is Usually an Artifact of Measurement Error. J Clin Endocrinol Metab 2022 107(6):1662-6.
3.
Kline GA, Symonds CJ, Billington EO. A retrospective review of the community medicine needs from osteoporosis services in Canada. BMC Endocr Disord 2022; 10.1186/s12902-022-01000-y.
4.
Kline GA, Morin SM, Lix L, Leslie WD. Fracture risk in Asian-Canadians is significantly over-estimated by the CAROC prediction tool: retrospective cohort study.Arch Osteoporosis 2022;17(1):133.
5.
Kline GA, Morin SN, Lix LM, McCloskey EV, Harvey NC, Kanis JA, Leslie WD. General comorbidity indicators contribute to fracture risk independent of FRAX: registry-based cohort study. J Clin Endocrinol Metab 2023;108(3):745-54.
6.
Whittier DE, Manske SL, Billington EO, Walker REA, Schneider PS, Burt LA, Hanley DA, Boyd SK. Hip Fractures in Older Adults Are Associated With the Low Density Bone Phenotype and Heterogeneous Deterioration of Bone Microarchitecture. J Bone Miner Res 2022; 37:1963-1972.
7.
Burt LA, Gabel L, Billington EO, Hanley DA, Boyd SK. Response to High-Dose Vitamin D Supplementation Is Specific to Imaging Modality and Skeletal Site. JBMR Plus 2022; e10615. DOI: 10.1002/jbm4.10615.
8.
Reid IR, Billington EO. Drug Therapy for Osteoporosis in Older Adults. The Lancet 2022; 399:1080-1092.
2021
1.
Billington EO, Mahajan A, Benham JL, Raman M. Effects of probiotics on bone mineral density and bone turnover: A systematic review. Crit Rev Food Sci Nutr 2021. DOI: 10.1080/10408398.2021.1998760.
2.
Riar S, Feasel AL, Aghajafari F, Symonds CJ, Kline GA, Billington EO. Comparison of 2 fracture risk estimation processes in Alberta: a cross-sectional chart review. CMAJ Open 2021; 9:E711-E717.
3.
Billington EO, Leslie WD, Brown JP, Prior JC, Morin SN, Kovacs CS, Kaiser SM, Lentle BC, Anastassiades T, Towheed T, Kline GA. Simulated Effects of Early Postmenopausal Bone Mineral Density Preservation on Long-term Fracture Risk: A Feasibility Study. Osteoporos Int 2021;32:1313-1320. Impact factor: 3.591.
4.
Kline GA, Morin SN, Lix LM. Leslie WD. Divergent patterns of anti-fracture medication use following fracture on therapy: a population-based cohort study. J Clin Endocrinol Metab 2021;107(2):491-9.
5.
Liu CS, Feasel AL, Kline GA, Billington EO. Pharmacotherapy decisions among postmenopausal women attending a group medical consultation or a one-on-one specialist consultation at an osteoporosis center. Osteoporos Int 2021;32:1421-1427. Impact factor: 3.591.
6.
Kline GA, Morin S, Lix L, Leslie WD. Patient outcomes in the years after a DXA-BMD treatment monitoring test: improved medication adherence but too little too late? J Bone Min Res 2021;36(8):1425-31.
7.
Kline GA, Morin SN, Feldman S, Lix LM, Leslie WD. Diminishing value from multiple serial bone densitometry in women receiving anti-resorptive medication for osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2021 106(9):2718-25.
2020
1.
Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. Billington EO, Burt LA, Rose MS, Davison EM, Gaudet S, Kan M, Boyd SK, Hanley DA. J Clin Endocrinol Metab. 2000;105(4).
2.
Postural balance effects associated with 400, 4000 or 10,000 IU vitamin D3 daily for three years: a secondary analysis of a randomized clinical trial. Burt LA, Gabel L, Billington EO, Hanley DA, Boyd SK. Nutrients 2020 12(2):527.
3.
At odds about the odds: women's choices to accept osteoporosis medications do not closely agree with physician-set treatment thresholds Billington EO, Feasel AL, Kline GA. J Gen Internal Med. 2020;35(1):276-282.
4.
Effect of high-dose vitamin D supplementation on peripheral arterial calcification: secondary analysis of a randomized clinical trial Billington EO, Burt LA, Plett R, Rose MS, Boyd SK, Hanley DA. Osteoporosis Int 2020.
5.
Longitudinal bone microarchitectural changes are best detected using image registration Kemp TD, de Bakker CMJ, Gabel L, Hanley DA, Billington EO, Burt LA, Boyd SK. Osteoporosis Int 2020.
6.
Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR. Mahajan A, Buse J, Kline GA. Osteoporosis Int 2020;31(1)203-7.
2019
1.
Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. JAMA 2019;322(8):736.
2.
Fibroblast growth factor 23 levels decline following sleeve gastrectomy Billington EO, Murphy R, Gamble GD, Callon K, Davies N, Plank LD, Booth M, Reid IR. Clin Endocrinol 2019;91(1):87.
3.
Skeletal fluorosis in a resettled refugee from Kakuma refugee camp Fabreau G, Bauman P, Whitford G, Kennel KA, Coakley AL, Johnston K, Gifford J, Sadrzadeh H, Whyte M, Kline GA. Lancet 2019;393(10168):223.
4.
Phosphate matters when investigating hypercalcemia: a mutation in SLC34A3 causing HHRH Tang AR, Hinz LE, Khan A, Kline GA. Endocrin Diab Metab Case Reports 2019 jul 26.
5.
Fracturing systemic skeletal histiocytosis of unknown type: a novel metabolic bone disease Saini R, diFrancesco LM, Johnston K, Khan A, Kline GA. Osteoporosis Int 2019 May 30.